Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future

Title: Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future

Volume: 14 Issue: 36

Author(s): Yasuyuki Fujita, Riichiro Abe and Hiroshi Shimizu

Affiliation:

Keywords: Anti-angiogenic agents, neoplasm, vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP), thalidomide

Abstract: Angiogenesis is a complex process which is critical for the growth, invasion, and metastasis of tumors. In the past ten years numerous new agents have been developed as angiogenesis inhibitors. Angiogenesis inhibitors can be classified by their targeted area of the angiogenic process; (1) VEGF and its receptors VEGFR (e.g. Bevacizumab); (2) tyrosine kinases within endothelial cells (Sunitinib); (3) proliferation of endothelial cells (Endostatin); (4) MMPs (Marimastat); (5) intercellular interactions via integrins (Cilengitide) and (6) combinations of the above mechanisms (Thalidomide). Some showed anti-tumor effects with objective responses and stable disease, and some disappeared from clinical use due to unexpected side effects or insufficient efficacies. Further investigations of combined therapies including angiogenesis inhibitors will shed light on the treatment of advanced and metastasized malignancies.

Cite this article as:

Fujita Yasuyuki, Abe Riichiro and Shimizu Hiroshi, Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future, Current Pharmaceutical Design 2008; 14 (36) . https://dx.doi.org/10.2174/138161208786898680